[go: up one dir, main page]

NO20071926L - Anvendelse av en mTOR-inhibitor i behandling av uterint leioyom. - Google Patents

Anvendelse av en mTOR-inhibitor i behandling av uterint leioyom.

Info

Publication number
NO20071926L
NO20071926L NO20071926A NO20071926A NO20071926L NO 20071926 L NO20071926 L NO 20071926L NO 20071926 A NO20071926 A NO 20071926A NO 20071926 A NO20071926 A NO 20071926A NO 20071926 L NO20071926 L NO 20071926L
Authority
NO
Norway
Prior art keywords
treatment
mtor inhibitor
uterine leiomyoma
leiomyoma
uterine
Prior art date
Application number
NO20071926A
Other languages
English (en)
Inventor
Jr Robert R Ruffolo
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20071926L publication Critical patent/NO20071926L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Air-Conditioning For Vehicles (AREA)

Abstract

Anvendelse av en mTOR-inhibitor ved behandling eller inhibering av fibroider.
NO20071926A 2004-10-28 2007-04-16 Anvendelse av en mTOR-inhibitor i behandling av uterint leioyom. NO20071926L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62291704P 2004-10-28 2004-10-28
PCT/US2005/039836 WO2006050461A1 (en) 2004-10-28 2005-10-21 Use of an mtor inhibitor in treatment of uterine leiomyoma

Publications (1)

Publication Number Publication Date
NO20071926L true NO20071926L (no) 2007-05-24

Family

ID=35768583

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071926A NO20071926L (no) 2004-10-28 2007-04-16 Anvendelse av en mTOR-inhibitor i behandling av uterint leioyom.

Country Status (17)

Country Link
US (1) US7528145B2 (no)
EP (1) EP1804779A1 (no)
JP (1) JP2008518966A (no)
KR (1) KR20070070184A (no)
CN (1) CN101048152A (no)
AU (1) AU2005302004A1 (no)
BR (1) BRPI0518079A (no)
CA (1) CA2585840A1 (no)
CR (1) CR9068A (no)
EC (1) ECSP077426A (no)
IL (1) IL182748A0 (no)
MX (1) MX2007005153A (no)
NI (1) NI200700111A (no)
NO (1) NO20071926L (no)
RU (1) RU2007112787A (no)
WO (1) WO2006050461A1 (no)
ZA (1) ZA200703446B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1478648B1 (en) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
CN101583347A (zh) * 2006-11-14 2009-11-18 阿里亚德医药股份有限公司 口服制剂
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
JP2008305262A (ja) * 2007-06-08 2008-12-18 Konica Minolta Business Technologies Inc サーバ及びシンクライアント環境でのプリンタ紹介方法
US20110098241A1 (en) * 2008-04-14 2011-04-28 Poniard Pharmaceuticals, Inc. Rapamycin analogs as anti-cancer agents
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US8492110B2 (en) * 2009-04-10 2013-07-23 Haiyan Qi Anti aging agents and methods to identify them
EP2763985B1 (en) * 2011-10-07 2016-06-22 Cellzome Limited {(4-(4-morpholino-dihydrothieno[3,4-d]pyrimidin-2-yl)aryl}urea or carbamate derivatives as mtor inhibitors

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316885A (en) * 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4650803A (en) * 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5023264A (en) * 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
US5023263A (en) 1990-08-09 1991-06-11 American Home Products Corporation 42-oxorapamycin
US5023262A (en) * 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
US5221670A (en) * 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5233036A (en) * 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
US5120842A (en) * 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) * 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) * 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) * 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5162333A (en) * 1991-09-11 1992-11-10 American Home Products Corporation Aminodiesters of rapamycin
US5177203A (en) * 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
US5256790A (en) * 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5489680A (en) * 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5411967A (en) * 1992-10-13 1995-05-02 American Home Products Corporation Carbamates of rapamycin
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5480988A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5434260A (en) * 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5262423A (en) * 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5260300A (en) * 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5504091A (en) * 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5378836A (en) * 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5391730A (en) * 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5373014A (en) * 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5385908A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5385910A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
US5385909A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5389639A (en) * 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5463048A (en) * 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US5491231A (en) * 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5665591A (en) * 1994-12-06 1997-09-09 Trustees Of Boston University Regulation of smooth muscle cell proliferation
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
CA2235036A1 (en) 1995-11-08 1997-05-15 University Of South Florida Guinea pig model for leiomyomas and atherosclerosis
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
WO1998002441A2 (en) 1996-07-12 1998-01-22 Ariad Pharmaceuticals, Inc. Non immunosuppressive antifungal rapalogs
US5989591A (en) * 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
JP2002511878A (ja) 1997-07-01 2002-04-16 アセロジエニクス・インコーポレイテツド 抗酸化剤による過増殖状態の治療の増強
US6015815A (en) * 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
JP2000012799A (ja) * 1998-06-25 2000-01-14 Nec Ic Microcomput Syst Ltd 半導体メモリ装置とその製造方法
AU783158B2 (en) 1999-08-24 2005-09-29 Ariad Pharmaceuticals, Inc. 28-epirapalogs
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
WO2002013802A2 (en) * 2000-08-11 2002-02-21 Wyeth Method of treating estrogen receptor positive carcinoma
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
US20030144204A1 (en) * 2001-12-19 2003-07-31 Baylor College Of Medicine Akt-based inducible survival switch
TWI307277B (en) * 2002-07-30 2009-03-11 Wyeth Corp Parenteral formulations
RU2005106855A (ru) * 2002-08-12 2005-10-10 Дзе Риджентс оф дзе Юниверсити оф Мичиган (US) Диагностика и лечение заболеваний, вызываемых дефектами каскада реакций, обусловливающих туберозный склероз
US20040077677A1 (en) 2002-09-17 2004-04-22 Wyeth Oral formulations
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
AR043504A1 (es) * 2003-03-17 2005-08-03 Novartis Ag Composiciones farmaceuticas que comprenden rapamicina para el tratamiento de enfermedades inflamatorias
DK1658295T3 (da) 2003-08-07 2007-09-24 Wyeth Corp Regioselektiv syntese af CCI-779

Also Published As

Publication number Publication date
EP1804779A1 (en) 2007-07-11
BRPI0518079A (pt) 2008-11-04
RU2007112787A (ru) 2008-12-10
ECSP077426A (es) 2007-05-30
AU2005302004A1 (en) 2006-05-11
US20060094745A1 (en) 2006-05-04
CA2585840A1 (en) 2006-05-11
NI200700111A (es) 2008-01-17
JP2008518966A (ja) 2008-06-05
WO2006050461A1 (en) 2006-05-11
US7528145B2 (en) 2009-05-05
MX2007005153A (es) 2007-06-26
KR20070070184A (ko) 2007-07-03
ZA200703446B (en) 2010-10-27
IL182748A0 (en) 2007-09-20
CR9068A (es) 2007-10-01
CN101048152A (zh) 2007-10-03

Similar Documents

Publication Publication Date Title
NO20071926L (no) Anvendelse av en mTOR-inhibitor i behandling av uterint leioyom.
DK1610770T3 (da) Anvendelse af en IBAT-inhibitor til behandling eller profylakse af forstoppelse
NO20070933L (no) Indazoler anvendbare i behandling av kardiovaskulaere sykdommer
CR8540A (es) Inhibidores de serina proteasa ns-3 del vhc
DE602005004630D1 (de) Elektrochirurgische Vorrichtung in der Umfangrichtung zur Behandlung der Hämorrhoiden
EP1755661A4 (en) USE OF GELSOLINE FOR THE TREATMENT OF INFECTIONS
DE502005007515D1 (de) Elektrochirurgisches instrument
ATE394077T1 (de) Prolaps-reparatur
MX2008006592A (es) Composiciones de edulcorante de alta potencia con calcio y composiciones edulcoradas con la misma
DE602005012825D1 (de) Diphenylimidazopyrimidin- und -imidazolamine als b-sekretase-inhibitoren
EP1755391A4 (en) METHOD AND COMPOSITIONS FOR TREATING NERVOUS ELEMENTS
DE602005006938D1 (de) Gebrauchslimitierendes elektronisches Schlüsselsystem für Plasmagerät zur Behandlung von Gewebeoberflächen
DK1586319T3 (da) Thiadiazolidinoner som GSK-3-inhibitorer
EP1653970A4 (en) GSK-3 HEMMER AND ITS USES
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
EP1765288A4 (en) METHOD FOR THE TREATMENT OF ENDOBRONCHIAL INFECTIONS
NO20071127L (no) Triazoloftalaziner
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
WO2007143211A3 (en) Methods for identifying agents and their use for the prevention of restenosis
DE502004004192D1 (de) Drehknopf eines bediengerätes
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
NO20043313L (no) Anvendelse av COX-2 inhibitorer i kombinasjon med antivirale midler for behandling av Papilloma virus infeksjoner
ATE445402T1 (de) Neue verwendung von pde5-hemmern
EP1913954A4 (en) MEDIUM AND METHODS BASED ON THE USE OF THE EDA DOMAIN OF FIBRONECTIN
DE502005007105D1 (de) 4-amino-5-oxo-8-phenyl-5h-pyrido-ä2,3-dü-pyrimidin-derivate als inhibitoren der tyrosinkinasen und der raf-kinasen zur behandlung von tumoren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application